At what price did Mark A. Goldsmith’s RVMD share sale occur?

The reported weighted average sale price was $156.1188 per share. The transaction was executed in multiple trades within a price range from $156.1105 to $156.8250, with the weighted average figure disclosed in the filing as the summary transaction price.

Revolution Medicines director sells 10,020 shares under plan

Revolution Medicines director and officer Mark A. Goldsmith reported an open-market sale of 10,020 shares of common stock on June 16, 2026 at a weighted average price of $156.1188 per share.

Filing Impact

(Very High)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Revolution Medicines director and officer Mark A. Goldsmith reported an open-market sale of 10,020 shares of common stock on June 16, 2026 at a weighted average price of $156.1188 per share. The transaction was executed under a pre-arranged Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy tax withholding obligations from restricted stock unit vesting.

Following this sale, Goldsmith directly holds 267,330 shares of Revolution Medicines common stock, which includes 182,938 restricted stock units and 652 shares acquired under the company’s Employee Stock Purchase Plan. He also has additional indirect holdings through family revocable trusts.

Insider Trade Summary 10b5-1

Net Seller: 10,020 shares

Net Sell 4 txns

Insider GOLDSMITH MARK A

Role See Remarks

Sold 10,020 shs ($1.56M)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,020	$156.1188	$1.56M
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 267,330 shares (Direct); Common Stock — 722,908 shares (Indirect, Trust)

Footnotes (7)

F1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.
F2. This transaction was executed in multiple trades at prices ranging from $156.1105 to $156.8250. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3. Includes 182,938 restricted stock units.
F4. Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026.
F5. Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
F6. Held by Jonathan Goldsmith Revocable Trust.
F7. Held by Rebecca Goldsmith Revocable Trust.

Key Figures

Shares sold: 10,020 shares Weighted average sale price: $156.1188 per share Direct holdings after transaction: 267,330 shares +4 more

7 metrics

Shares sold 10,020 shares Open-market sale on June 16, 2026

Weighted average sale price $156.1188 per share Open-market sale on June 16, 2026

Direct holdings after transaction 267,330 shares Common stock directly held following June 16, 2026 sale

Restricted stock units included 182,938 RSUs Included in direct holdings after transaction

ESPP shares included 652 shares Acquired under Employee Stock Purchase Plan on May 31, 2026

Trust holding example 64,424 shares Indirect common stock holding reported through a trust

Additional trust holding example 594,060 shares Another indirect common stock holding reported through a trust

Key Terms

Rule 10b5-1, restricted stock units, Employee Stock Purchase Plan, Revocable Living Trust

4 terms

Rule 10b5-1 regulatory

"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

restricted stock units financial

"to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs")"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Employee Stock Purchase Plan financial

"Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026."

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Revocable Living Trust financial

"Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Revolution Medicines (RVMD) shares did Mark A. Goldsmith sell?

Mark A. Goldsmith sold 10,020 shares of Revolution Medicines common stock. The sale occurred on June 16, 2026 at a weighted average price of $156.1188 per share in an open-market transaction disclosed in a Form 4 filing.

Why did Mark A. Goldsmith sell RVMD shares according to the Form 4?

The sale was made under a Rule 10b5-1 instruction letter adopted on May 31, 2023. According to the filing, it was specifically designed to satisfy Goldsmith’s tax withholding obligations arising from the vesting of restricted stock units after July 15, 2023.

How many Revolution Medicines (RVMD) shares does Mark A. Goldsmith hold after the sale?

After the reported sale, Goldsmith directly holds 267,330 shares of Revolution Medicines common stock. This direct position includes 182,938 restricted stock units and 652 shares acquired under the company’s Employee Stock Purchase Plan, as detailed in the Form 4 footnotes.

What indirect RVMD holdings does Mark A. Goldsmith report through trusts?

The filing lists indirect holdings through revocable trusts, including shares held by the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust, the Jonathan Goldsmith Revocable Trust, and the Rebecca Goldsmith Revocable Trust, reflecting additional exposure held in trust form.

How are restricted stock units reflected in Mark A. Goldsmith’s RVMD holdings?

Goldsmith’s direct holdings include 182,938 restricted stock units. These RSUs represent rights to receive shares of Revolution Medicines common stock in the future, and are counted within the 267,330 directly held shares disclosed after the reported sale transaction.

Did Mark A. Goldsmith acquire RVMD shares through an Employee Stock Purchase Plan?

Yes. The filing notes that his holdings include 652 shares acquired under Revolution Medicines’ Employee Stock Purchase Plan. These shares were purchased on May 31, 2026 and are part of his reported direct ownership following the June 16, 2026 sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/18/2026 - 04:11 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOLDSMITH MARK A

(Last)

(First)

(Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY

CALIFORNIA

94063

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/16/2026		S⁽¹⁾		10,020	D	$156.1188⁽²⁾	267,330⁽³⁾⁽⁴⁾	D
Common Stock								594,060	I	Trust⁽⁵⁾
Common Stock								64,424	I	Trust⁽⁶⁾
Common Stock								64,424	I	Trust⁽⁷⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

2. This transaction was executed in multiple trades at prices ranging from $156.1105 to $156.8250. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. Includes 182,938 restricted stock units.

4. Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026.

5. Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

6. Held by Jonathan Goldsmith Revocable Trust.

7. Held by Rebecca Goldsmith Revocable Trust.

Remarks:

President and Chief Executive Officer

	/s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR